Legal status · Canada
Is BGM1812 legal in Canada?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. BGM1812 is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 3 human studies are cited on its profile.
BGM1812 in Canada at a glance
| Classification | Investigational, not approved |
|---|---|
| Health Canada approval status | Not approved by Health Canada; investigational |
| Human studies cited | 3 of 5 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the BGM1812 profile, checked against Health Canada, Health Products and Food Branch (Health Canada) listings at the reviewed date.
What this means
- 01
BGM1812 is being studied in registered clinical trials but has not received Health Canada marketing approval in Canada.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What BGM1812 is
A dual amylin and calcitonin receptor agonist from BrightGene, derived from the structure of petrelintide, with one medicinal chemistry paper reporting animal and in vitro results and two phase 1 trials recruiting in China and the United States. No human data have been published.
BGM1812 is a peptide developed by BrightGene Bio-Medical Technology in Suzhou, China, as a dual amylin and calcitonin receptor agonist (DACRA) for obesity. Its only publication is the discovery paper in the Journal of Medicinal Chemistry (July 2025), which describes it as the product of three rounds of structure-guided modification starting from petrelintide, the long-acting amylin analogue then in phase 2, using molecular dynamics simulations to compensate for the absence of structure-activity data.
Mechanism: Amylin receptors are formed from the calcitonin receptor together with receptor activity modifying proteins; a dual amylin and calcitonin receptor agonist activates both the amylin receptor complexes and the calcitonin receptor alone. In animals, DACRAs reduce food intake and body weight through hindbrain satiety circuits and slow gastric emptying, and the field's working hypothesis, reviewed in 2026, is that calcitonin receptor engagement may increase efficacy while also influencing nausea and aversion.
Regulatory history: Not approved. Two phase 1 trials (NCT07224399 in the United States, NCT07294235 in China) listed as recruiting with safety primary outcomes; no results posted; no human data published.
How Health Canada treats this kind of product
Authorises drugs for sale through a Notice of Compliance and Drug Identification Number. A compound that is not authorised for sale cannot lawfully be sold for human use, and personal importation of prescription drugs is limited.
The classification above is the The Longevity Archive reading of Health Canada, Health Products and Food Branch listings for BGM1812 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
BGM1812 in other countries
Frequently asked questions
Is BGM1812 legal in Canada?
No. BGM1812 is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 3 human studies are cited on its profile.
Can I buy BGM1812 in Canada?
No approved product exists to buy. In Canada BGM1812 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is BGM1812 Health Canada approved?
No. In Canada BGM1812 is classified as "Investigational, not approved", which is not a Health Canada marketing approval. For comparison, the US FDA status is: Not approved. Two phase 1 trials (NCT07224399 in the United States, NCT07294235 in China) listed as recruiting with safety primary outcomes; no results posted; no human data published.. On the evidence, 3 human studies are cited on its profile.
Related compounds in Canada
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for BGM1812 live on its compound profile.
BGM1812 profileThis page is general information about the regulatory status of BGM1812 in Canada, current as of Sep 2026. It is not legal advice, and classifications change; check Health Canada, Health Products and Food Branch directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.